Bristol-Myers Squibb stops combination immunotherapy clinical trial due to positive interim results

Bristol-Myers Squibb (BMS) has reported positive phase 3 results for its clinical trial of a combination of immunotherapy drugs nivolumab (Opdivo) plus ipilimumab (Yervoy) for the treatment of people with previously untreated, advanced or metastatic renal cell carcinoma (RCC). This has led to the trial being stopped early following a planned interim analysis of the survival data. […]

read more

How treatments have changed for advanced or metastatic renal cell carcinoma (RCC) over the past decade and a look at potential new treatments for the future

During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then progressively approved for first-line […]

read more

International Clinical Trials Day 20th May 2017

This coming Saturday 20th May is International Clinical Trials Day, which has been held on 20th May each year since 2005 to commemorate the day James Lind started the first clinical trial. The National Institute for Health Research (NIHR) are launching a campaign called ‘I Am Research’ to raise awareness of the benefits of research and […]

read more

Durable response after stopping immunotherapy for kidney cancer

A recent study presented at the American Society for Clinical Oncology (ASCO) 2017 Genitourinary Cancer Symposium held in Orlando, Florida last month, reported a sustained response to PD-1/PD-L1 immunotherapy in patients with metastatic renal cell carcinoma (RCC) who had stopped treatment due to immune-related adverse events. This durable response lasted for more than 6 months […]

read more

Everolimus (Afinitor) recommended by NICE for use by NHS England for advanced kidney cancer that has been previously treated

Everolimus (Afinitor) has been recommended by the National Institute for Health and Care Excellence (NICE) for use by NHS England for people with advanced renal cell carcinoma (RCC) that has progressed during or after treatment with a vascular endothelial growth factor (VEGF) targeted therapy. This decision has been made following a reconsideration of everolimus by […]

read more

Ever wondered how and why we do clinical research?

Find out the answers to this and much more in the National Institute for Health Research (NIHR) free online course, available to anyone wanting to understand more about clinical research. Entitled ‘Improving Healthcare through Clinical Research’, the course will run for 6 weeks from 6 June 2016. It is a flexible approach to learning; you can […]

read more

Christy Watson talks about renal cancer

Christy talks about her experience and why she’s hosting her 3rd Green Ribbon Ball – she’s raised more than £75,000 for the charity. Get in touch at Renal Cancer Research Fund, Scotland. During the interview, Christy talks about her experience of being on a kidney cancer clinical trial, symptoms of kidney cancer, and the reason for starting […]

read more

Be Clear on Cancer “Blood in Pee” Campaign

NHS England’s Be Clear on Cancer ‘Blood in Pee’ campaign was launched on 15 February 2016. The campaign will run for almost seven weeks across England with the aim of raising awareness of a key symptom of both bladder and kidney cancers – blood in pee. The campaign encourages people who notice blood in their pee to […]

read more
Showing 261 to 268 of 268 results
  TOP